86506-70-9

Basic information

• Product Name: 2-[2-(oxiran-2-yl)ethyl]-1H-isoindole-1,3(2H)-dione
• CAS NO: 86506-70-9
• Molecular Formula: C₁₂H₁₁NO₃
• Molecular Weight: 217.2206
• Mol File: 86506-70-9.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 359.5°C at 760 mmHg
• Flash Point: 171.2°C
• Density: 1.353g/cm³
• Vapor Pressure: 2.36E-05mmHg at 25°C
• Refractive Index: 1.612
• CAS DataBase Reference: 2-[2-(oxiran-2-yl)ethyl]-1H-isoindole-1,3(2H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[2-(oxiran-2-yl)ethyl]-1H-isoindole-1,3(2H)-dione(86506-70-9)
• EPA Substance Registry System: 2-[2-(oxiran-2-yl)ethyl]-1H-isoindole-1,3(2H)-dione(86506-70-9)

Safety Data

• Hazardous Substances Data: 86506-70-9(Hazardous Substances Data)

Usage

General Description

2-[2-(oxiran-2-yl)ethyl]-1H-isoindole-1,3(2H)-dione, also known as epirubicin, is a chemotherapeutic agent used in the treatment of various forms of cancer, including breast, lung, and bladder cancer. It belongs to the anthracycline family of antibiotics and works by inhibiting the growth of cancer cells. Epirubicin is administered intravenously and is commonly used in combination with other cancer drugs. Its mechanism of action involves binding to DNA and interfering with the synthesis of RNA and proteins, ultimately leading to the death of cancer cells. Common side effects of epirubicin include nausea, vomiting, hair loss, and an increased risk of infection due to its effects on the bone marrow. Overall, epirubicin has proven to be an effective and important tool in the fight against cancer.

Upstream product

• 136918-14-4 phthalimide 
• 1074-82-4 potassium phtalimide 
• 13287-42-8 (2-bromoethyl)oxirane 
• 52898-32-5 N-(3-butenyl)phthalimide 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 

Downstream Products

• 944344-35-8 2-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)isoindoline-1,3-dione 
• 944344-36-9 2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)-3-hydroxybutyl)isoindoline-1,3-dione 
• 1584155-01-0 (R)-2-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-fluorobutyl)isoindoline-1,3-dione 
• 1584155-00-9 (R)-2-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)isoindoline-1,3-dione 
• 1301178-77-7 2-(3-fluoro-4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-isoindoline-1,3-dione 
• 1301178-76-6 2-(3-fluoro-4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)isoindoline-1,3-dione 
• 1144854-24-9 2-(3-hydroxy-4-(4-(2-propoxyphenyl)piperazin-1-yl)butyl)isoindoline-1,3-dione 
• 1039747-40-4 C₃₃H₃₆N₄O₃ 
• 227776-12-7 2-(4-(4-diphenylmethyl-piperazin-1-yl)-3-hydroxy-butyl]isoindolin-1,3-dione 
• 402921-65-7 2-(4-{benzyl-[2-(bis-pyridin-2-ylmethylamino)ethyl]amino}-3-hydroxybutyl)phthalimide 

Relevant articles and documents

Design, synthesis, and biological evaluation of 2-(benzylamino-2-hydroxyalkyl)isoindoline-1,3-diones derivatives as potential disease-modifying multifunctional anti-Alzheimer agents

The complex nature of Alzheimer's disease calls for multidirectional treatment. Consequently, the search for multi-target-directed ligands may lead to potential drug candidates. The aim of the present study is to seek multifunctional compounds with expected activity against disease-modifying and symptomatic targets. A series of 15 drug-like various substituted derivatives of 2-(benzylamino-2-hydroxyalkyl)isoindoline-1,3-diones was designed by modification of cholinesterase inhibitors toward β-secretase inhibition. All target compounds have been synthesized and tested against eel acetylcholinesterase (eeAChE), equine serum butyrylcholinesterase (eqBuChE), human β-secretase (hBACE-1), and β-amyloid (Aβ-aggregation). The most promising compound, 12 (2-(5-(benzylamino)-4-hydroxypentyl)isoindoline-1,3-dione), displayed inhibitory potency against eeAChE (IC50 = 3.33 μM), hBACE-1 (43.7% at 50 μM), and Aβ-aggregation (24.9% at 10 μM). Molecular modeling studies have revealed possible interaction of compound 12 with the active sites of both enzymes-acetylcholinesterase and β-secretase. In conclusion: modifications of acetylcholinesterase inhibitors led to the discovery of a multipotent anti-Alzheimer's agent, with moderate and balanced potency, capable of inhibiting acetylcholinesterase, a symptomatic target, and disease-modifying targets: β-secretase and Aβ-aggregation.

High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice

The dopamine D3 receptor (D3R) is a promising target for the development of pharmacotherapeutics to treat substance use disorders. Several D3R-selective antagonists are effective in animal models of drug abuse, especially

Synthesis and evaluation of fluoro substituted pyridinylcarboxamides and their phenylazo analogues for potential dopamine D3 receptor PET imaging

A series of fluoro substituted pyridinylcarboxamides and their phenylazo analogues with high affinity and selectivity for the dopamine D3 receptor was synthesized by the use of 6-fluoropyridine-3-carbonyl chloride (1) and fluorophenylazocarboxylic ester (